56.8 F
New York
Wednesday, November 30, 2022



Shineco, Inc. to Create A New Platform for Psychological Rehabilitation of Tumor Patients

the Platform to conduct research on critical topics, introduce the results of relevant research into the Company's tumor clinical treatment system, and improve the development of Shineco's digital tumor diagnosis and treatment.

Shineco, Inc. Announces Strategic Alliance to Enhance the R&D of Innovative Drugs and Medical Devices

Both Shineco and JSY are poised to seize these opportunities to increase market share in the innovative drug and medical device industry by relying on their business advantages and their synergy cooperation. 

Shineco, Inc. Enters Cooperation Agreement to Explore High-end Medical Imaging Devices Field and Produce PET

Both parties will produce 100 PET tumor precision imaging inspection devices within 2022, and it is expected to achieve sales revenue of RMB750 million (approximately $118 million).

Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

Professor Sun will lead the research and innovation of the company’s tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment.

Interview with Dr. Peng He: why invest in the digital medical market and cancer prevention and treatment?

technological development, market evolution, and the COVID-19 pandemic, digital medical and healthcare management industries are ushering in significant development opportunities.

Yoshitsu Co., Ltd debuts on Nasdaq: how the Japanese beauty retailer expanded its business during COVID-19

On Tuesday, Yoshitsu Co., Ltd, a Japanese beauty and health products retailer and wholesaler, debuted on the Nasdaq Stock Exchange under the ticker symbol “TKLF”, raising $25 million in its initial public offering (IPO).

Shineco Is Ambitious to Develop Rapid-acting Antidepressant Natural Innovative Medicine

Shineco, Inc. (NASDAQ: SISI) shows its ambition to contribute to the long-term development of the biomedical industry and the treatment of depression globally.

Chinese Financial Services Firm Sentage Holdings Prices IPO At $5 To Raise $20 Million

Jason Lin As the first Chinese company which went public in the U.S. after the Didi crisis, Shanghai-based financial services firm Sentage Holdings debuted on...

China-based Pop Culture Group IPO: Shares Surge 405%

While Didi Global's (ticker: DIDI) $4.4 billion IPO was big enough to stand out in the U.S. markets, another China-based company Pop Culture Group (ticker: CPOP) skyrocketed 405% to win the best first-day performance on Wednesday.

Latest news